Haley D. Frerichs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haley D. Frerichs has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Sophia Pin
Cross Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada
2 shared publications Allison Sivak
1 shared publication- Ananya Beruar
Division of Radiation Oncology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Cross Cancer Institute, 11560 University Avenue NW, Edmonton, AB T6G 1Z2, Canada
1 shared publication - Armin Rouhi
Department of Surgery, University of Alberta, Edmonton, AB T6G 2B7, Canada
1 shared publication - Cheng-Han Lee
Department of Laboratory Medicine and Pathology University of Alberta Edmonton Alberta Canada
1 shared publication - Christa Aubrey
Division of Gynecologic Oncology, Department of OBGYN, University of Alberta, Edmonton, AB, Canada
1 shared publication
Latest Publications
- Open Access
Clinicopathologic Characteristics, Molecular Profile, Treatment, and Recurrence in Endometrial Cancer with Pelvic Lymph Node Isolated Tumor Cells
Objective: Our objective was to characterize the molecular–pathologic profile and recurrence patterns of endometrial cancer with pelvic lymph node isolated tumor cells (ITCs). Methods: A single-center retrospective study of patients with endometrial cancer and ITCs was conducted. Patients with concurrent lymph nodes or distant metastasis were excluded. Cases were reviewed by a gynecologic pathologist, and electronic medical records were reviewed. Descriptive statistics were performed using R 4.4.2. Results: A total of 43 patients were included, with a median follow-up time of 33 months. The majority were endometrioid carcinoma (91%) and stage I (72%). In total, 28 (65%) were MMR-proficient and p53-wild-type (MMRp p53wt), nine (21%) were MMR-deficient (MMRd), six (14%) were p53-abnormal (p53abn), and none were POLE-mutated (POLEmut). Additionally, 27 (96%) MMRp p53wt cases showed a microcystic, elongated, and fragmented (MELF) pattern of invasion. Adjuvant therapy was indicated in 38 (88%) patients; 32 (74%) received therapy and six (14%) declined. Four (9.3%) patients recurred, with a recurrence rate of 33% (2/6) for p53abn, 11% (1/9) for MMRd, and 4% (1/28) for MMRp p53wt. All recurrences were to distant sites. In the MMRp p53wt group, 16 (57%) had external beam radiation (EBRT) +/− vaginal brachytherapy (VBT), three (11%) had chemotherapy +/− radiation, and nine (32%) had no adjuvant treatment or VBT alone. Conclusions: Molecular profile is prognostically relevant in endometrial carcinoma with ITCs. ITCs in MMRp p53wt endometrioid carcinoma present a low risk of disease recurrence. As the majority of our cohort received adjuvant therapy, future work may explore de-escalating treatment in low-risk ITC cases.
Open AccessClinicopathologic Characteristics, Molecular Profile, Treatment, and Recurrence in Endometrial Cancer with Pelvic Lymph Node Isolated Tumor Cells
Objective: Our objective was to characterize the molecular–pathologic profile and recurrence patterns of endometrial cancer with pelvic lymph node isolated tumor cells (ITCs). Methods: A single-center retrospective study of patients with endometrial cancer and ITCs was conducted. Patients with concurrent lymph nodes or distant metastasis were excluded. Cases were reviewed by a gynecologic pathologist, and electronic medical records were reviewed. Descriptive statistics were performed using R 4.4.2. Results: A total of 43 patients were included, with a median follow-up time of 33 months. The majority were endometrioid carcinoma (91%) and stage I (72%). In total, 28 (65%) were MMR-proficient and p53-wild-type (MMRp p53wt), nine (21%) were MMR-deficient (MMRd), six (14%) were p53-abnormal (p53abn), and none were POLE-mutated (POLEmut). Additionally, 27 (96%) MMRp p53wt cases showed a microcystic, elongated, and fragmented (MELF) pattern of invasion. Adjuvant therapy was indicated in 38 (88%) patients; 32 (74%) received therapy and six (14%) declined. Four (9.3%) patients recurred, with a recurrence rate of 33% (2/6) for p53abn, 11% (1/9) for MMRd, and 4% (1/28) for MMRp p53wt. All recurrences were to distant sites. In the MMRp p53wt group, 16 (57%) had external beam radiation (EBRT) +/− vaginal brachytherapy (VBT), three (11%) had chemotherapy +/− radiation, and nine (32%) had no adjuvant treatment or VBT alone. Conclusions: Molecular profile is prognostically relevant in endometrial carcinoma with ITCs. ITCs in MMRp p53wt endometrioid carcinoma present a low risk of disease recurrence. As the majority of our cohort received adjuvant therapy, future work may explore de-escalating treatment in low-risk ITC cases.
- Open Access
- 28 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 317
Endometrial Cancer Recurrence Risk Following Robotic Hysterectomy
Background: Minimally invasive surgery is widely used in endometrial cancer management, but recurrence remains a concern. Methods: A retrospective review of 1201 patients treated from 2012 to 2019 with robotic laparoscopy was conducted. Recurrence-free survival and hazard ratios were calculated using multivariate Cox models. Results: Of 1278 patients, 155 cases of recurrent disease were identified. Age (HR 1.01, p = 0.045), LVSI (HR 3.54, p < 0.001), stage and high-grade histology (HR 3.39, p < 0.001) were associated with increased risk of recurrence. Hazard ratios for stages IB, II and III/IV were 1.92 (p = 0.007), 2.67 (p = 0.001), and 3.23 (p < 0.001) respectively. The use of a uterine manipulator was an independent risk factor on multivariate analysis (HR 2.12, p < 0.001). Adjuvant chemotherapy (HR 0.67, p = 0.239) and radiotherapy (HR 0.64, p = 0.056) trends favored reduced risk but were not significant. Chemoradiotherapy was found to have a reduction in recurrence with a HR 0.44 (p = 0.002). Conclusions: Traditional prognostic factors remain important for patients with endometrial cancer having undergone robotic laparoscopic hysterectomy. Uterine manipulator use should be carefully reconsidered in endometrial cancer surgery.
- 28 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 317
Open AccessEndometrial Cancer Recurrence Risk Following Robotic Hysterectomy
Background: Minimally invasive surgery is widely used in endometrial cancer management, but recurrence remains a concern. Methods: A retrospective review of 1201 patients treated from 2012 to 2019 with robotic laparoscopy was conducted. Recurrence-free survival and hazard ratios were calculated using multivariate Cox models. Results: Of 1278 patients, 155 cases of recurrent disease were identified. Age (HR 1.01, p = 0.045), LVSI (HR 3.54, p < 0.001), stage and high-grade histology (HR 3.39, p < 0.001) were associated with increased risk of recurrence. Hazard ratios for stages IB, II and III/IV were 1.92 (p = 0.007), 2.67 (p = 0.001), and 3.23 (p < 0.001) respectively. The use of a uterine manipulator was an independent risk factor on multivariate analysis (HR 2.12, p < 0.001). Adjuvant chemotherapy (HR 0.67, p = 0.239) and radiotherapy (HR 0.64, p = 0.056) trends favored reduced risk but were not significant. Chemoradiotherapy was found to have a reduction in recurrence with a HR 0.44 (p = 0.002). Conclusions: Traditional prognostic factors remain important for patients with endometrial cancer having undergone robotic laparoscopic hysterectomy. Uterine manipulator use should be carefully reconsidered in endometrial cancer surgery.
- Open Access
- 15 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3827
Does the Addition of a Collis Gastroplasty to Antireflux Surgery Reduce Hiatal Hernia Recurrence?: A Systematic Review and Meta-Analysis
Introduction: The role of Collis gastroplasty has traditionally been reserved for patients with a shortened esophagus due to chronic gastroesophageal reflux disease (GERD). However, its necessity has been questioned, leading to a decline in popularity. This systematic review and meta-analysis aimed to evaluate the efficacy of hiatal hernia repair with fundoplication, with versus without Collis gastroplasty. Methods: A systematic search of Ovid MEDLINE, Ovid Embase, Scopus, Web of Science Core Collection, and the Cochrane Library (via Wiley) was performed in May 2025. Studies were included if they compared outcomes or the safety profile of Collis gastroplasty versus no Collis gastroplasty during fundoplication for hiatal hernia repair. Meta-analyses were conducted using a random-effects model and restricted maximum likelihood. Results: Of 664 unique results, 17 studies comprising 4048 patients were included. There was a female predominance (65.4%), with a weighted mean age of 58.9 ± 14.0 years and follow-up of 43.5 ± 43.1 months. Patients who underwent Collis gastroplasty represented 35.8% of the cohort. Nissen fundoplication was the most common procedure in both the Collis (91.9%) and non-Collis (84.5%) groups. Most studies had selection bias, in which only patients who did not have sufficient intraoperative intra-abdominal esophageal length underwent Collis gastroplasty. Recurrence rates were similar (13.5% vs. 13.2%). Collis gastroplasty was not associated with a reduction in hiatal hernia recurrence (OR 0.53, 95% CI 0.23–1.22). Symptom outcomes, including regurgitation (OR 0.53, 95% CI 0.05–5.39), reflux (OR 0.81, 95% CI 0.03–22.12), dysphagia (OR 1.12, 95% CI 0.62–2.04), and use of antireflux medication on follow-up (OR 1.15, 95% CI 0.62–2.15), were not significantly different. However, Collis gastroplasty was associated with a higher risk of complications, including overall complications (OR 2.63, 95% CI 1.55–4.46), leak (OR 3.35, 95% CI 1.11–10.05), and surgical site infection (OR 8.28, 95% CI 1.16–59.10). There were no significant differences in abscess formation (OR 5.97, 95% CI 0.77–46.49), length of stay (mean difference 0.36 days, 95% CI −0.30 to 1.01), readmission (OR 1.13, 95% CI 0.36–3.60), reoperation (OR 1.24, 95% CI 0.64–2.41), or mortality (OR 1.08, 95% CI 0.45–2.57). Conclusions: Collis gastroplasty was not associated with a decreased risk of hiatal hernia recurrence or improvement in other efficacy measures, but this is in the context of a strong component of selection bias. In this context, there may be a role for Collis gastroplasty in difficult cases if the rate of recurrence does not differ from those with sufficient length, but this must be balanced against a significantly increased risk of complications.
- 15 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3827
Open AccessDoes the Addition of a Collis Gastroplasty to Antireflux Surgery Reduce Hiatal Hernia Recurrence?: A Systematic Review and Meta-Analysis
Introduction: The role of Collis gastroplasty has traditionally been reserved for patients with a shortened esophagus due to chronic gastroesophageal reflux disease (GERD). However, its necessity has been questioned, leading to a decline in popularity. This systematic review and meta-analysis aimed to evaluate the efficacy of hiatal hernia repair with fundoplication, with versus without Collis gastroplasty. Methods: A systematic search of Ovid MEDLINE, Ovid Embase, Scopus, Web of Science Core Collection, and the Cochrane Library (via Wiley) was performed in May 2025. Studies were included if they compared outcomes or the safety profile of Collis gastroplasty versus no Collis gastroplasty during fundoplication for hiatal hernia repair. Meta-analyses were conducted using a random-effects model and restricted maximum likelihood. Results: Of 664 unique results, 17 studies comprising 4048 patients were included. There was a female predominance (65.4%), with a weighted mean age of 58.9 ± 14.0 years and follow-up of 43.5 ± 43.1 months. Patients who underwent Collis gastroplasty represented 35.8% of the cohort. Nissen fundoplication was the most common procedure in both the Collis (91.9%) and non-Collis (84.5%) groups. Most studies had selection bias, in which only patients who did not have sufficient intraoperative intra-abdominal esophageal length underwent Collis gastroplasty. Recurrence rates were similar (13.5% vs. 13.2%). Collis gastroplasty was not associated with a reduction in hiatal hernia recurrence (OR 0.53, 95% CI 0.23–1.22). Symptom outcomes, including regurgitation (OR 0.53, 95% CI 0.05–5.39), reflux (OR 0.81, 95% CI 0.03–22.12), dysphagia (OR 1.12, 95% CI 0.62–2.04), and use of antireflux medication on follow-up (OR 1.15, 95% CI 0.62–2.15), were not significantly different. However, Collis gastroplasty was associated with a higher risk of complications, including overall complications (OR 2.63, 95% CI 1.55–4.46), leak (OR 3.35, 95% CI 1.11–10.05), and surgical site infection (OR 8.28, 95% CI 1.16–59.10). There were no significant differences in abscess formation (OR 5.97, 95% CI 0.77–46.49), length of stay (mean difference 0.36 days, 95% CI −0.30 to 1.01), readmission (OR 1.13, 95% CI 0.36–3.60), reoperation (OR 1.24, 95% CI 0.64–2.41), or mortality (OR 1.08, 95% CI 0.45–2.57). Conclusions: Collis gastroplasty was not associated with a decreased risk of hiatal hernia recurrence or improvement in other efficacy measures, but this is in the context of a strong component of selection bias. In this context, there may be a role for Collis gastroplasty in difficult cases if the rate of recurrence does not differ from those with sufficient length, but this must be balanced against a significantly increased risk of complications.
- Open Access
- 24 January 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 63
Adverse childhood experiences, obesity, and endometrial cancer: A case series and scoping review
- 24 January 2026
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 63
Open AccessAdverse childhood experiences, obesity, and endometrial cancer: A case series and scoping review